Effects of Cariporide and Losartan on Hypertrophy, Calcium Transients, Contractility, and Gene Expression in Congestive Heart Failure
Key result
Losartan and cariporide improved cellular contractility by 55% and 30%, respectively, and reduced elevated systolic calcium by 86% and 27% in rats with postinfarction heart failure.
Why the study?
Does cariporide or losartan improve cardiac function, remodeling, and calcium regulation in a rat model of postinfarction heart failure?
Population
Female Sprague-Dawley rats with large myocardial infarctions and sham controls
Comparison
Losartan or cariporide treated for 49 days vs Placebo
Design
Preclinical, randomized
Follow-up
49 days
Authors
Discussion
Loading...
Member takes
Implication
Supports targeted research on calcium handling in postinfarction HF models; clinical translation remains untested.
Study Design
Type
RCT
Structured PICO
Does cariporide or losartan improve cardiac function, remodeling, and calcium regulation in a rat model of postinfarction heart failure?
P
Population
Female Sprague-Dawley rats with large myocardial infarctions and sham controls
I
Intervention
Losartan or cariporide treated for 49 days (started 7 days post-infarction)
C
Comparator
Placebo
O
Outcome
Cardiac function, gene expression, cell dimensions, shortening, relaxation, and calcium transientssurrogate
In a rat model of postinfarction heart failure, both losartan and cariporide improved cardiomyocyte contractility and calcium regulation, but only losartan attenuated postinfarction remodeling.
Cite This Study
Loennechen et al. (2002) conducted an RCT in Postinfarction heart failure. Losartan and cariporide vs. Placebo was evaluated on Cardiac function, gene expression, cell dimensions, shortening, relaxation, and calcium transients. Losartan and cariporide improved cellular contractility by 55% and 30%, respectively, and reduced elevated systolic calcium by 86% and 27% in rats with postinfarction heart failure.